UB-TT170
Overview:
Chimeric Antigen Receptor (CAR) T-cells for immunotherapy of cancer are being developed. These CAR T-cells overcome several limitations of current strategies including the ability to tune CAR T-cell activity and even completely “turn-off” the activated CAR T-cells. UB-TT170 is an ex vivo engineered autologous TagCAR T cell designed for the treatment of osteosarcomas.